/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

M

Michael Kreuter

Johannes Gutenberg University Mainz(DE)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

759

Papers

17.9K

Citations

68

h-index

218

i10-index

Michael Kreuter is an academic researcher from Johannes Gutenberg University Mainz. The author has contributed to research in topics: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis & Sarcoidosis and Beryllium Toxicity Research & Medical Imaging and Pathology Studies. The author has an h-index of 68, co-authored 646 publications.

ORCID: 0000-0003-4402-2159

Research Topics

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Sarcoidosis and Beryllium Toxicity Research Medical Imaging and Pathology Studies Systemic Sclerosis and Related Diseases Chronic Obstructive Pulmonary Disease (COPD) Research

Papers by this author

works

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

2019 · The Lancet Respiratory Medicine · 606 citations

https://doi.org/10.1016/s2213-2600(19)30341-8

Toby M. Maher Tamera J. Corte Aryeh Fischer Michael Kreuter

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

2021 · The Lancet Respiratory Medicine · 490 citations

https://doi.org/10.1016/s2213-2600(20)30554-3

Jürgen Behr Antje Prasse Michael Kreuter Johannes Johow

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

2021 · The Lancet Respiratory Medicine · 490 citations

https://doi.org/10.1016/s2213-2600(20)30554-3

Jürgen Behr Antje Prasse Michael Kreuter Johannes Johow

Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype

2004 · Journal of Clinical Investigation · 286 citations

https://doi.org/10.1172/jci21378

Diane R. Bielenberg Yasuhiro Hida Akio Shimizu Arja Kaipainen

The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements

2020 · The Lancet Rheumatology · 286 citations

https://doi.org/10.1016/s2665-9913(19)30144-4

Anna‐Maria Hoffmann‐Vold Toby M. Maher E. Philpot Ali Ashrafzadeh

Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis

2018 · JAMA · 221 citations

https://doi.org/10.1001/jama.2018.6129

Ganesh Raghu Bernt van den Blink Mark J. Hamblin Alison Brown

Research topics

topics

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Sarcoidosis and Beryllium Toxicity Research

Medical Imaging and Pathology Studies

Systemic Sclerosis and Related Diseases

Chronic Obstructive Pulmonary Disease (COPD) Research

Chat about Author

Papers

Chat

Click to start Chat